Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan


To determine whether Suboxone can be effectively used to treat Taiwanese ethnic subjects with opiate dependence.

Full Title of Study: “An Open Multi-center Trial of Suboxone® (Buprenorphine/Naloxone) Treatment Among Opiate-Dependent Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2009


  • Drug: Buprenorphine + naloxone (Suboxone)
    • Sublingual tablets
  • Drug: Buprenorphine + naloxone (Suboxone)

Arms, Groups and Cohorts

  • Experimental: Suboxone, maximum 8mg
  • Experimental: Buprenorphine + naloxone
  • Experimental: Buprenorphine + naloxone (Suboxone)

Clinical Trial Outcome Measures

Primary Measures

  • Retention in treatment
    • Time Frame: weekly up to 13 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female subjects, 20 years of age or older at screening visit. – Subjects must meet DSM-IV/COWS1,2 criteria for opiate dependence. (COWS total score ≥5) – Subjects must have a positive urine drug screen (dipstick test) for an opiate or morphine at study entry – Subject is seeking treatment with the desire to discontinue opiate use as an initial goal but willing to consider and accept longer treatment if necessary. – Subject is in good physical health or, if he/she has a medical condition needing ongoing treatment, must be in the care of a physician who is willing to take responsibility for such treatment and work with the study physician. Study physicians able to manage the subject for his/her general medical condition, may be assigned this role. These same conditions apply in case of subjects with psychiatric disorder(s) needing ongoing treatment. – Subject is agreeable to and capable of signing informed consent form. – Females of childbearing potential must have a negative pregnancy test and agree to use a double barrier method or condoms/diaphragm and spermicide contraceptive method during the study. Exclusion Criteria:

  • Women who are pregnant, lactating or breast feeding. – Subjects have any acute medical condition that would make participation, in the opinion of the treating physician or the principal investigator, medically hazardous (e.g., acute hepatitis, unstable cardiovascular, liver or renal disease). – Subjects have clinically significant liver disease. – Subjects who have demonstrated a previous hypersensitivity to buprenorphine or naloxone. – Subjects who are considered an immediate risk for suicide, are acutely psychotic, severely depressed, or in need of inpatient treatment. – Subjects who are dependent on alcohol, benzodiazepines or other drugs of abuse (except tobacco) to the point of requiring immediate medical attention. – Subjects received methadone treatment within the last 30 days since screening visit. – Subjects have any pending legal action that could prohibit continued participation. – Subjects have participated in other clinical studies within the past 30 days. – Subjects who are expecting to leave the clinic geographic area prior to study completion.

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Indivior Inc.
  • Collaborator
    • Taipei City Psychiatric Center, Taiwan
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Shih-Ku Lin, MD, Principal Investigator, Department of Psychiatry, Taipei City Psychiatric Center, Taipei, Taiwan.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.